COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study

Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
doi: https://doi.org/10.1101/2022.07.18.22277757

Article Information

doi 
https://doi.org/10.1101/2022.07.18.22277757
History 
  • July 18, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Mohammad Shehab1,*,
  2. Fatema Alrashed2 and
  3. Ahmad Alfadhli1
  1. 1Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Aljabreyah 46300, Kuwait
  2. 2Department of Pharmacy Practice, Faculty of Pharmacy, Health Sciences Center (HSC), Kuwait University, Jabriya, Kuwait
  1. ↵*Correspondence: Mohammad Shehab; E-mail:moshehab{at}moh.gov.kw; Tel.: +965-99633181
Back to top
Posted July 18, 2022.
Download PDF

Supplementary Material

Data/Code
Email
COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study
Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
medRxiv 2022.07.18.22277757; doi: https://doi.org/10.1101/2022.07.18.22277757
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area